var _paq = window._paq = window._paq || []; /* tracker methods like "setCustomDimension" should be called before "trackPageView" */ _paq.push(['trackPageView']); _paq.push(['enableLinkTracking']); (function() { var u=""; _paq.push(['setTrackerUrl', u+'matomo.php']); _paq.push(['setSiteId', '1']); var d=document, g=d.createElement('script'), s=d.getElementsByTagName('script')[0]; g.async=true;'//'; s.parentNode.insertBefore(g,s); })();

RWR Insights | What’s in a name? The humble (confusing) non-interventional study and the anti-definition

[Click on the image to return to the monthly report index page]


The FDA definition for non-interventional studies is intuitively actionable. We, as researchers, can (confidently) classify our study based on the parameters provided, which in turn allows us to identify the applicable regulations and guidelines and build our study playbook to describe what we need to do (regulatory requirements) and what we should consider (regulatory considerations) depending on the intended use of the RWE we generate.

4 MARCH 2024 – In his latest Guest Column, Stuart McCully (Real-World Research Ltd) discusses the differing definitions of non-interventional studies in Europe and the US, and the need for clarity when discussing these studies in real-world evidence (RWE) generation.

Read the full article HERE.

Related Posts

RWR CONTEXT At first glance, the General Practice Data for Planning and Research (GPDPR) seems innocuous. The UK’s NHS is making GP patient data available for research purposes. What isn’t made clear, is that this is an ‘opt out’ [...]

RWR CONTEXT The EMA references this standard in the context of non-interventional post-authorisation safety studies (PASS) as: “Relevant scientific guidance should be considered [= Recommendation, not a legal mandate] by marketing authorisation holders and investigators for the development of [...]

Go to Top